Success Metrics

Clinical Success Rate
86.7%

Based on 13 completed trials

Completion Rate
87%(13/15)
Active Trials
3(15%)
Results Posted
69%(9 trials)
Terminated
2(10%)

Phase Distribution

Ph phase_2
4
20%
Ph phase_3
5
25%
Ph phase_1
3
15%
Ph phase_4
6
30%

Phase Distribution

3

Early Stage

4

Mid Stage

11

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
3(16.7%)
Phase 2Efficacy & side effects
4(22.2%)
Phase 3Large-scale testing
5(27.8%)
Phase 4Post-market surveillance
6(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.3%

13 of 16 finished

Non-Completion Rate

18.8%

3 ended early

Currently Active

3

trials recruiting

Total Trials

20

all time

Status Distribution
Active(3)
Completed(13)
Terminated(3)
Other(1)

Detailed Status

Completed13
Recruiting3
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
3
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (16.7%)
Phase 24 (22.2%)
Phase 35 (27.8%)
Phase 46 (33.3%)

Trials by Status

unknown15%
completed1365%
withdrawn15%
recruiting315%
terminated210%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT07090161Phase 2

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Recruiting
NCT06961968Phase 3

Randomized Withdrawal Study in Patients With Schizophrenia

Recruiting
NCT05648591Phase 4

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Recruiting
NCT00254202Phase 3

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Completed
NCT04819776Phase 3

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Completed
NCT05344365Phase 2

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Withdrawn
NCT01291511Phase 3

Relapse Prevention Study in Patients With Schizophrenia

Completed
NCT04712734Phase 1

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Completed
NCT01498770

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed
NCT04127058Phase 1

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Completed
NCT01917318Phase 2

Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

Terminated
NCT02600741

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed
NCT02413918Phase 4

Iloperidone in Mixed States of Bipolar Disorder

Completed
NCT01464229Phase 4

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

Completed
NCT01920802Phase 4

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

Completed
NCT01929889Phase 4

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

Terminated
NCT02453893Phase 3

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Unknown
NCT01623713Phase 2

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Completed
NCT01207414Phase 4

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

Completed
NCT01529294Phase 1

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20